St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine whether the herbal product St. John's wort is safe and effective in treating generalized social anxiety disorder (GSAD).

Study hypothesis: Hypericum perforatum (St. John's wort) is more effective in treating GSAD than placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Criteria

Inclusion Criteria:

• Diagnosis of GSAD

• Brief Social Phobia Scale (BSPS) score of 20 or higher

Exclusion Criteria:

• Comorbid anxiety, depressive, or bipolar disorders

• Schizophrenia

• Cognitive impairment

• Substance abuse or dependence within 1 year prior to study entry

• Any unstable medical condition

• Clinically significant laboratory or electrocardiogram (EKG) abnormality

• Currently use psychotropic medications or may need psychotropic medication during the study

• Psychotherapy within 6 weeks prior to study entry

• Failed a previous trial of St. John's wort at doses of 1800 mg/day or greater

• Pregnancy or breastfeeding